Malaria Clinical Trial
Official title:
Field Efficacy Of Insecticide Treated Uniforms And Skin Repellents To Reduce Malaria Incidence In Military Personnel On Active Duty In Regions Of Hyperendemicity
Purpose
While there is strong evidence that permethrin treated clothing prevents insect bites there
is insufficient evidence from trials to demonstrate a reduction in infections. The evidence
that topical insect repellants prevent malaria is more robust, but studies in civilian
suffer from poor compliance. It is not known if there is an added benefit from combining the
two. The effectiveness of permethrin-treated uniforms with and without DEET lotion are
compared in a 2x2 design in Mgambo Jeshi la Kujenga Taifa (JKT) military camp in Tanga
region.
The four arms are: 1) combined intervention group receiving permethrin treated uniform (PTU)
and 30% DEET (diethyl toluamide) liposome formula; 2) permethrin intervention group
receiving PTU and placebo lotion; 3) DEET intervention group receiving untreated army combat
uniform (ACU) and 30% DEET liposome formula; 4) placebo group receiving untreated ACU and
placebo lotion. Both participants and investigators will be blinded to treatment allocation.
The outcome measure is the incidence of Plasmodium falciparum malaria infection measured by
Polymerase Chain Reaction every month by active case detection.
The study is a prospective, cluster-randomised placebo controlled trial using a 4-arm
non-inferiority design with 12 months of follow-up. Healthy recruits of the Tanzanian
National Service Program JKT Mgambo Camp will be enrolled in the trial. The recruits come
from all over Tanzania. The transmission in the camp is relatively high: the incidence of
malaria infection in Mgambo camp among recruits in the last quarter of 2014 was 0.68 per
person per year measured by RDT.
One thousand five hundred recruits will be enrolled in the trial. Randomisation will be
based on combania (the company, comprising typically 30-50 recruits). Recruits in a combania
perform all activities together as a group. The randomisation will be unequal since the
investigators expect that the primary comparison requiring the greatest precision is that of
adding DEET lotion to PTU. Investigators will randomise 500 recruits for each arm of the
primary comparison (PTU plus DEET, PTU uniform only) and 250 recruits to each of DEET only
and placebo.
Compliance will be maximised by requesting participants to use their uniforms and lotions
only at night. Monitoring of uniform use will be conducted by random spot checks of
participants in the evenings by study staff. In addition, bottles of lotion will be weighed
on a monthly basis during active case detection as a direct measure of compliance with
lotion use.
Artemether-lumefantrine (Co-Artem) will be given to any participant with a temperature of
≥37.5 degrees centigrade or a history of fever in the past 48h, and P. falciparum parasites
detected by RDT in the absence of other detectable cause of fever.
The participants' activities for the previous two weeks will be recorded by questionnaire by
study staff during active case detection. Time away from the camp or in the sick bay and
prophylactic periods in the case of antimalarial treatment will be excluded from time at
risk.
Soldiers are a vulnerable group because they have limited ability to protect their own
interests. It is therefore, particularly important that they should be prevented from being
involved in the research project because they feel it is their duty to do so or that they
may be subject to penalty from senior members of the army. Therefore, in order to protect
the soldiers from coercion the ethical review process for the research is conducted the same
processes procedure as is required by a civilian Institutional Review Board (IRB). In
addition, service members' commanders or supervisors may not be in the room during the
consent process. It will be stressed to Tanzania People's Defence Force (TPDF) staff
performing spot checks that they are merely to monitor compliance and should not coerce
participants into wearing their uniforms when in the barracks
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04601714 -
Baseline Cohort Malaria Morbidity Study
|
||
Withdrawn |
NCT04020653 -
A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria
|
Phase 2 | |
Terminated |
NCT04368910 -
Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria
|
Phase 3 | |
Completed |
NCT03641339 -
Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
|
N/A | |
Completed |
NCT02544048 -
Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults
|
||
Completed |
NCT00527163 -
Role of Nitric Oxide in Malaria
|
||
Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
Active, not recruiting |
NCT04704674 -
Community Dynamics of Malaria Transmission in Humans and Mosquitoes in Fleh-la and Marshansue, Salala District, Bong County, Liberia
|
||
Completed |
NCT03276962 -
Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age
|
Phase 2 | |
Completed |
NCT04966871 -
Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults
|
Phase 1 | |
Completed |
NCT00289185 -
Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants
|
Phase 2 | |
Recruiting |
NCT03937817 -
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
|
||
Active, not recruiting |
NCT06153862 -
Africa Ready Malaria Screening
|
N/A | |
Completed |
NCT04545905 -
Antenatal Care as a Platform for Malaria Surveillance: Utilizing Community Prevalence Measures From the New Nets Project to Validate ANC Surveillance of Malaria in Burkina Faso
|
||
Recruiting |
NCT06278181 -
Diabetes, Metabolic Syndrome and Risk of Malaria in Cameroon
|
||
Withdrawn |
NCT02793388 -
A Trial on Supervised Primaquine Use in Ethiopia
|
Phase 4 | |
Withdrawn |
NCT02793414 -
Diagnostic Utility of Volatile Organic Compounds in Human Breath for Acute Clinical Malaria in Ethiopia
|
||
Completed |
NCT02793622 -
Prevention of Malaria in HIV-uninfected Pregnant Women and Infants
|
Phase 3 | |
Completed |
NCT02909712 -
Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania
|
Phase 2 | |
Completed |
NCT02315690 -
Evaluation of Reactive Focal Mass Drug Administration for Malaria Elimination in Swaziland
|
Phase 3 |